179 related articles for article (PubMed ID: 27286996)
1. Effect of renal function on pemetrexed-induced haematotoxicity.
Ando Y; Hayashi T; Ujita M; Murai S; Ohta H; Ito K; Yamaguchi T; Funatsu M; Ikeda Y; Imaizumi K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2016 Jul; 78(1):183-9. PubMed ID: 27286996
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.
Rombolà G; Vaira F; Trezzi M; Chiappini N; Falqui V; Londrino F
J Nephrol; 2015 Apr; 28(2):187-91. PubMed ID: 24986522
[TBL] [Abstract][Full Text] [Related]
7. Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
Schlei Z; Tan W; Faber MG; Chen H; Meagher A; Dy GK
Clin Lung Cancer; 2018 Nov; 19(6):467-475. PubMed ID: 30369425
[TBL] [Abstract][Full Text] [Related]
8. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
Nowak AK; Cook AM; McDonnell AM; Millward MJ; Creaney J; Francis RJ; Hasani A; Segal A; Musk AW; Turlach BA; McCoy MJ; Robinson BW; Lake RA
Ann Oncol; 2015 Dec; 26(12):2483-90. PubMed ID: 26386124
[TBL] [Abstract][Full Text] [Related]
12. Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration-induced nephropathy.
Mitarai Y; Tanino R; Nakashima K; Hotta T; Isobe T; Tsubata Y
Br J Clin Pharmacol; 2023 Dec; 89(12):3551-3560. PubMed ID: 37452621
[TBL] [Abstract][Full Text] [Related]
13. Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma.
Youk J; Park H; Jin KN; Moon HJ; Yang MS; Kim KH; Kim JS
Korean J Intern Med; 2017 May; 32(3):563-565. PubMed ID: 27889955
[No Abstract] [Full Text] [Related]
14. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
Honoré PH; Joensen SJ; Olsen M; Hansen SH; Mellemgaard A
Cancer Chemother Pharmacol; 2014 Aug; 74(2):349-57. PubMed ID: 24934863
[TBL] [Abstract][Full Text] [Related]
15. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
16. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
17. Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed/carboplatin combination chemotherapy.
Araki R; Keira T; Masuda Y; Tanaka T; Yamada H; Hamamoto T
J Clin Pharm Ther; 2019 Apr; 44(2):276-284. PubMed ID: 30552862
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
19. Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
Singh N; Baldi M; Kaur J; Muthu V; Prasad KT; Behera D; Bal A; Gupta N; Kapoor R
Cancer; 2019 Jul; 125(13):2203-2212. PubMed ID: 30825389
[TBL] [Abstract][Full Text] [Related]
20. Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma.
Valerio S; Bracale UM; Giribono AM; Viviani E; Caioni F; del Guercio L
Ann Ital Chir; 2014 Nov; 85(ePub):. PubMed ID: 25586574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
